Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.56 USD
Change Today +0.0249 / 4.61%
Volume 648.5K
As of 8:04 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Open
$0.55
Previous Close
$0.54
Day High
$0.57
Day Low
$0.53
52 Week High
03/4/15 - $1.23
52 Week Low
07/24/15 - $0.53
Market Cap
63.3M
Average Volume 10 Days
698.2K
EPS TTM
$-0.46
Shares Outstanding
112.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Treasurer and Direct...
Total Annual Compensation: $584.6K
Founder, Chairman and President
Total Annual Compensation: $393.3K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $247.9K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $213.2K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $197.4K
Compensation as of Fiscal Year 2014.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Expands Its Phase I Study for Treatment of Anal Warts inHIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

CEL-SCI Corporation announced it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection). Dr. Joel Palefsky has joined the study as a Principal Investigator at the University of California San Francisco (UCSF). UCSF becomes the second clinical site for the study. The first site, the U.S. Naval Medical Center San Diego, continues to enroll patients under a Cooperative Research and Development Agreement (CRADA).

CEL-SCI Corporation Presents at AFund Triple Gold Investment Conference, Jul-22-2015 11:20 AM

CEL-SCI Corporation Presents at AFund Triple Gold Investment Conference, Jul-22-2015 11:20 AM. Venue: The Princeton Club, 15 West 43rd Street, 2nd Floor, New York, NY 10036, United States.

CEL-SCI Corporation Updates on June Patient Enrollment in its Phase 3 Head and Neck Cancer Trial

CEL-SCI Corporation reported that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in just diagnosed, not yet treated patients with head and neck cancer. The company said that total patient enrollment is now 488 as of June 30, in the large Phase 3 study in head and neck cancer. A total of 880 patients are expected to be enrolled, through approximately 100 clinical centers in about 25 countries by the end of March 2016. The company noted the Multikine Phase 3 study is enrolling just diagnosed, not yet treated patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care (SOC) vs. subjects who are treated with SOC only. Standard of Care for these patients consists of the surgical removal of the tumor and any locally involved lymph nodes, followed by radiotherapy or concurrent radiochemotherapy. Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. Multikine is designed to be a different type of therapy in the fight against cancer: one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Multikine is also being tested in a Phase 1 study under a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Center, San Diego, as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. CEL-SCI has also entered into two co-development agreements with Ergomed Clinical Research Limited to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.56 USD +0.0249

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies
 

Industry Analysis

CVM

Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.9x
Price/Book 144.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 135.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit www.cel-sci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.